



Healius Limited 2022 AGM report

ASX code	HLS
Meeting date	20 October 2022
Type of meeting	Hybrid
Monitor	Patricia Beal, assisted by Elizabeth Fish
Pre AGM-meeting	Yes with Chair Jenny McDonald, Janet Payne (Investor Relations) and (by web) Sally Evans (Rem Chair)

Meeting Statistics

Number of holdings represented by ASA	54
Number of shares represented by ASA	385,734
Value of shares represented by ASA	\$1.26 million
Total number attending meeting	105 total: 27 shareholders (22 in person; 5 online); guests 78 in total
Market capitalisation	\$1.8 billion
ASA open proxies voted	On a poll, ASA voted in favour of all the resolutions.

The mood of the addresses and the attendees was optimistic. The company will be much simpler going forward, with basically diagnostics (pathology plus Imaging) being the ongoing business. Day Hospitals will be sold. It was explained that owning day hospitals put HLS in competition (servicing those hospitals as customers of the diagnostics business) with servicing other 'customers' (other hospitals and GPs etc who also order diagnostic tests). Staff have shown their dedication to patients and HLS culture during the waves of Omicron during the year.

Existing businesses (entirely in Australia) will be improved, and new opportunities explored and developed including through the new acquisition of agilex.

ASA and one other shareholder asked questions, which were answered very satisfactorily.

All items of business were approved with at least 96% of cast votes in favour.

This document has been prepared by the Australian Shareholders Association Limited ABN 40 000 625 669 ("ASA"). It is not a disclosure document, it does not constitute investment or legal advice and it does not take into account any person's particular investment objectives. The statements and information contained in this document are not intended to represent recommendations of a particular course of action to any particular person. Readers should obtain their own independent investment and legal advice in relation to the matters contemplated by this document. To the fullest extent permitted by law, neither ASA nor any of its officers, directors, employees, contractors, agents or related bodies corporate:

- makes any representations, warranties or guarantees (express or implied) as to the accuracy, reliability, completeness or fitness for purpose of any statements or information contained in this document; or*
- shall have any liability (whether in contract, by reason of negligence or negligent misstatement or otherwise) for any statements or information contained in, or omissions from this document; nor for any person's acts or omissions undertaken or made in reliance of any such statements, information or omissions.*

This document may contain forward looking statements. Such statements are predictions only and are subject to uncertainties. Given these uncertainties, readers are cautioned not to place reliance on any such statements. Any such statements speak only to the date of issue of this document and ASA disclaims any obligation to disseminate any updates or revisions to any such statements to reflect changed expectations or circumstances.